Resources
Resources
CODING & DOCUMENTATION
EDUCATION & EVENTS
ENROLLMENT & CREDENTIALING
FORMS & MANUALS
HEALTHCARE INFORMATION & TECHNOLOGY
PATIENT HEALTH
PHARMACY
POLICIES & GUIDELINES
PRE-SERVICE REVIEW
PROGRAMS & INITIATIVES
PROVIDER NETWORKS & SPECIALTIES
Coding for RSV Product Beyfortus Administration
The infant respiratory syncytial virus (RSV) product BeyfortusTM (nirsevimab) has specific coding requirements for administration that differ from other routine immunizations.
Use the following codes when administering this vaccine:
These codes are subject to change. Refer to the AAP coding guidelines for the most up-to-date coding for reporting the administration of nirsevimab.
Note: Administration CPT codes 90460–90461 or 90471–90472 should not be reported for the immunization administration for the injection of nirsevimab, as these codes are limited to the administration of vaccine and toxoid products.
Because nirsevimab is a monoclonal antibody, it should not be reported with ICD-10 code Z23 (Encounter for immunization). The correct ICD-10 code is Z29.11 (Encounter for prophylactic immunotherapy for RSV).